![](/wp-content/uploads/2023/11/Screenshot-2023-11-29-at-4.57.56-PM.png)
$599
SAB Initiates Ph1 T1DM study; Lilly Continues Verve Investment; Arecor Expands Collaboration with Lilly; Avidity Expands CV Partnership with BMS
Four cardiometabolic-related news items have been observed from SAB Biotherapeutics, Verve/Lilly, Arecor/Lilly, and Avidity/BMS. Below, FENIX provides highlights and insights for the respective news items.